Acute heart failure - Basic pathomechanism and new drug targets

Herz

Volumn 31, Issue 8, 2006, Pages 727-735

  Rupp, Heinz ^a   Rupp, Thomas P ^b   Alter, Peter ^b   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NONE

Author keywords

DHA; EPA; Etomoxir; Fatty acid oxidation; Heart failure; Metabolism; Omacor; Omega 3 fatty acid ethyl ester; Sudden cardiac death

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE INHIBITOR; DOCOSAHEXAENOIC ACID; ETOMOXIR; ICOSAPENTAENOIC ACID; OXFENICINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ACUTE HEART FAILURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; REVIEW;

ACUTE DISEASE; ANTI-ARRHYTHMIA AGENTS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; FATTY ACIDS, OMEGA-3; HUMANS;

EID: 33845575790     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2911-x     Document Type: Review

References (54)

1. Alter P, Rupp H, Czerny F, et al. Relation of ventricular wall stress and autonomic tone in patients with dilated cardiomyopathy assessed by cardiac magnetic resonance imaging. Eur Heart J 2006;27:Abstract Suppl:678.
2. Bakewell L, Burdge GC, Calder PC. Polyunsaturated fatty acid concentrations in young men and women consuming their habitual diets. Br J Nutr 2006;96:93-9.
3. Barger PM, Brandt JM, Leone TC, et al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105:1723-30.
4. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006;113:799-805.
5. Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 1970;218:153-9.
6. Brilla CG, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz 2003;28:744-53.
7. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-9.
8. Burdge GC, Wootton SA. Conversion of alpha-linolenicacid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002;88:411-20.
9. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 1994;26:1371-5.
10. De Brouwer KF, Degens H, Aartsen WM, et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J Mol Cell Cardiol 2006;40:838-45.
11. Degens H, de Brouwer KF, Gilde AJ, et al. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 2006;101:17-26.
12. Doggrell SA, Brown L. D-sotalol: death by the SWORD or deserving of further consideration for clinical use? Expert Opin Investig Drugs 2000;9:1625-34.
13. Eichelbaum M, Kroemer HK, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett 1992;64-65:115-22.
14. El Armouche A, Boknik P, Eschenhagen T, et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation 2006;114:670-80.
15. Feinendegen LE, Henrich MM, Kuikka JT, et al. Myocardial lipid turnover in dilated cardiomyopathy: a dual in vivo tracer approach. J Nucl Cardiol 1995;2:42-52.
16. Fernandez-Velasco M, Goren N, Benito G, et al. Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol 2003;553:395-405.
17. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int J Vitam Nutr Res 1998;68:159-73.
18. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
19. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995;25:560-3.
20. Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003;108:2883-91.
21. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999;33:1399-405.
22. Jacob R, Brandle M, Dierberger B, et al. Functional consequences of cardiac hypertrophy and dilatation. Basic Res Cardiol 1991;86:Suppl 1:113-30.
23. Janicki JS, Brower GL, Gardner JD, et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 2006;69:657-65.
24. Kearney MT, Fox KA, Lee AJ, et al. Predicting sudden death in patients with mild to moderate chronic heart failure. Heart 2004;90:1137-43.
25. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
26. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005;112:2762-8.
27. Leaf A, Xiao YF, Kang JX, et al. Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Pharmacol Ther 2003;98:355-77.
28. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-8.
29. Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999;17:S3-7.
30. Lionetti V, Linke A, Chandler MP, et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 2005;66:454-61.
31. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001;22:2085-103.
32. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903.
33. Nair SS, Leitch J, Falconer J, et al. Cardiac (n-3) non-esterified fatty acids are selectively increased in fish oil-fed pigs following myocardial ischemia. J Nutr 1999;129:1518-23.
34. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
35. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-91.
36. Rupp H, Benkel M, Maisch B. Control of cardiomyocyte gene expression as drug target. Mol Cell Biochem 2000;212:135-42.
37. Rupp H, Rupp TP, Maisch B. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure? Cardiovasc Res 2005;66:423-6.
38. Rupp H, Schulze W, Vetter R. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition byetomoxir. Am J Physiol 1995;269:R630-40.
39. Rupp H, Turcani M, Ohkubo T, et al. Dietary linolenic acid-mediated increase in vascular prostacyclin formation. Mol Cell Biochem 1996;162:59-64.
40. Rupp H, Wagner D, Rupp T, et al. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Herz 2004;29:673-85.
41. Rupp H, Wahl R, Hansen M. Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum. J Appl Physiol 1992;72:352-60.
42. Sack MN, Disch DL, Rockman HA, et al. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A 1997;94:6438-43.
43. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27-35.
44. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22:479-86.
45. Stanton LW, Garrard LJ, Damm D, et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res 2000;86:939-45.
46. Steiner S, Wahl D, Mangold BL, et al. Induction of the adipose differentiation-related protein in liver of etomoxir-treated rats. Biochem Biophys Res Commun 1996;218:777-82.
47. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 1988;11:416-26.
48. Trenkwalder P, Ruland D, Stender M, et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY). J Hypertens 1994;12:709-16.
49. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997;96:3681-6.
50. Turcani M, Rupp H. Modification of left ventricular hypertrophy by chronic etomoxir treatment. Br J Pharmacol 1999;126:501-7.
51. Van de Werf F, Ardissino D, Betriu A, et al. W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
52. Vetter R, Rupp H. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins. Am J Physiol 1994;267:H2091-9.
53. Vogt M, Jacob R, Kissling G, et al. Chronic cardiac reactions. II. Mechanical and energetic consequences of myocardial transformation versus ventricular dilatation in the chronically pressure-loaded heart. Basic Res Cardiol 1987;82:Suppl 2:147-59.
54. Zarain-Herzberg A, Rupp H. Transcriptional modulators targeted at fuel metabolism of hypertrophied heart. Am J Cardiol 1999;83:31H-7H.